Related Experiment Video

Updated: Jun 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Novel targeted agents on the horizon for castration-resistant prostate cancer

Anthony Koupparis1, Rowan G Casey, Rowan Casey

  • 1The Vancouver Prostate Centre & Department of Urological Sciences, 2775 Laurel St., Vancouver, BC, Canada.

Future Oncology (London, England)
|December 15, 2010
PubMed

Insights

Prostate cancer patients can develop resistance to androgen deprivation treatment, progressing to castration-resistant prostate cancer (CRPC). Understanding the complex mechanisms driving CRPC is crucial for developing effective targeted therapies.

Area of Science:

  • Oncology
  • Urology
  • Molecular Biology

Background:

  • Androgen deprivation therapy is a standard treatment for prostate cancer.
  • Resistance to this therapy leads to castration-resistant prostate cancer (CRPC), which has a poor prognosis.
  • CRPC development involves complex biological processes facilitating cancer cell survival and growth.

Purpose of the Study:

  • To discuss the pathways involved in the development of CRPC.
  • To highlight mechanisms driving castrate resistance.
  • To focus on targeted therapies developed from understanding these mechanisms.

Main Methods:

  • Review of current literature on CRPC.
  • Discussion of molecular mechanisms underlying treatment resistance.
  • Analysis of pathways contributing to CRPC progression.

Main Results:

  • CRPC arises from multiple processes including clonal selection and androgen receptor axis reactivation.
  • Stress-induced prosurvival genes and alternative growth factor pathways contribute to resistance.
  • Understanding these mechanisms has informed the development of novel targeted therapies.

Conclusions:

  • Resistance to androgen deprivation therapy is a significant challenge in prostate cancer management.
  • Multiple interconnected pathways contribute to the transition to CRPC.
  • Targeted therapies based on elucidated mechanisms offer new hope for CRPC patients.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...